Cantor Fitzgerald reiterates USD 12 target for CytomX Therapeutics stock

Published on 10/20/2026 at 20:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue was USD 1.42 million versus USD 12.39 million expected. CytomX Therapeutics stock costs EUR 2.26 on October 20, 2026, up 8.11 percent on Nasdaq.

Analyst target and results

Cantor Fitzgerald reiterated a USD 12.00 target and Overweight rating on October 13, 2026.
Second-quarter 2026 revenue was USD 1.42 million versus USD 12.39 million expected.
CytomX stock costs EUR 2.26 at Lang & Schwarz on October 20, 2026 at 8:01 p.m. CEST, up 8.11 percent on Nasdaq.
Market capitalization was USD 551.2 million as of October 20, 2026.

CTMX, US23284F1057, Illustration mit AI erstellt.

CytomX Therapeutics (ISIN US23284F1057) remains tied to a USD 12.00 price target after Cantor Fitzgerald reiterated its Overweight rating on October 13, 2026, according to Investing.com. CytomX Therapeutics stock was trading at EUR 2.26 at Lang & Schwarz on October 20, 2026 at 8:01 p.m. CEST, up 8.11 percent on Nasdaq.

Target contrasts with second-quarter revenue

Cantor Fitzgerald maintained the USD 12.00 target while describing CytomX as a clinical-stage oncology company approaching a potential phase-three program in 2027, Investing.com reported on October 13, 2026. The target is USD 9.47, or 374.31 percent, above the USD 2.53 Nasdaq price cited by the financial data for October 20, 2026 at 2:02 p.m. ET.

CytomX reported USD 1.42 million of revenue for the second quarter of 2026, down from USD 10.26 million in the first quarter. The company also reported a net loss of USD 20.67 million and diluted earnings per share of minus USD 0.09 for the second quarter, according to Investing.com.

Stock position and valuation

CytomX stock had a USD 2.20 to USD 8.21 52-week range and a USD 551.2 million market capitalization as of October 20, 2026. Its latest USD 2.53 Nasdaq price was 8.11 percent above the prior close of USD 2.34, while the quoted volume was 1,890,946 shares.

The company held USD 17.22 million in cash and cash equivalents at June 30, 2026, against USD 381.23 million in total assets. Its operating cash flow for the second quarter was negative USD 18.07 million, keeping cash use central to the investment case.

Comparison with peers

CytomX: up 8.11 percent, P/E minus 5.65, market capitalization USD 551.2 million as of October 20, 2026.

Iovance Biotherapeutics (Nasdaq, USD): up 4.71 percent, P/E minus 20.38, market capitalization USD 6.7 billion as of October 20, 2026.

Sarepta Therapeutics (Nasdaq, USD): up 9.75 percent, P/E minus 6.68, market capitalization USD 2.1 billion as of October 20, 2026.

Clinical pipeline remains central

CytomX describes its Probody platform as a way to conditionally activate antibody and cytokine therapies in the tumor environment while limiting activity in healthy tissue. The South San Francisco company lists collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna on its investor-relations page, CytomX Therapeutics states.

The combination of a USD 12.00 analyst target and USD 1.42 million quarterly revenue leaves clinical execution and cash use as the main numbers for investors to weigh.

The further course of trading is shown by the continuously updated real-time quote of CytomX Therapeutics stock.